Efficacy Study in Removing Excess Iron From the Heart

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-12-31

Study Completion Date

2004-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether deferiprone has superior efficacy in removing excess iron from the heart when compared with deferoxamine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major

NCT00103753

Beta-Thalassemia

UNKNOWN PHASE4

Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease

NCT00293098

Iron Overload

APPROVED_FOR_MARKETING

Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia

NCT01709032

Thalassemia Major With Severe Transfusional Iron Overload

COMPLETED PHASE1/PHASE2

Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload

NCT01459718

Transfusion-dependent β-thalassemia Patients Cardiac Iron Overload

TERMINATED PHASE2

Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients

NCT00349453

Hemochromatosis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a multi-center, randomized, open-label, controlled clinical trial. The study population is participants with thalassemia major who are receiving regular chelation therapy with deferoxamine. A total of sixty (60) participants will be enrolled among the investigative sites.

The primary objective of this study is to determine whether deferiprone exhibits superior efficacy in removing excess iron from the heart compared to that of the standard therapy, deferoxamine.

The secondary objective is to evaluate the relative efficacy of deferiprone with respect to that of deferoxamine as assessed by serum ferritin concentration and liver iron concentration.

The primary efficacy measure in this study will be the participants' cardiac iron status, as determined by heart MRI T2\* assessments.

The secondary efficacy measure will be by serum ferritin concentration and liver iron concentration. This will be measured by the Superconducting Quantum-Interference Device (SQUID) BioSusceptometer.

The duration of treatment is 12 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thalassemia Major Hemosiderosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ferriprox (deferiprone)

Intervention Type DRUG

Desferal (deferoxamine)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of thalassemia major as confirmed by laboratory and clinical criteria
* Participants who are well transfused-maintaining a mean pre-transfusion Hb (hemoglobin) no less than 9 g/dL.
* Between 18 and 36 years of age.
* Receiving ongoing chelation therapy with deferoxamine for at least the past five years. Those who have been exposed to deferiprone for

≤ 6 months but not within the last 2 years prior to commencement of this study will be considered eligible to participate.
* Abnormal heart MRI T2\* greater than or equal to 8 ms and \< 20 ms.
* If female, fertile, and is neither pregnant nor lactating, confirms she will use an effective method of contraception for the length of the trial and has a negative pregnancy test immediately prior to commencement of study drug OR has had a tubal ligation OR a hysterectomy OR is post menopausal (at least 1 year no menses prior to enrollment in the study) OR their only sexual partner has been sterilized (if male).
* If male and fertile, he confirms that he and/or his partner will use an effective method of contraception for the length of the trial.
* Provide a signed and witnessed written informed consent obtained prior to the first study intervention.

Exclusion Criteria

* Have anemia other than thalassemia.
* HIV antibody positive.
* Clinical evidence of cardiomyopathy as shown by LV Shortening Fraction \< 30 % and/or CMR derived LV (left ventricular) Ejection Fraction \< 56 %.
* Severe/significant arrhythmia, including those who have had atrial fibrillation (participants with occasional ectopic beats and normal echo can be included) or those requiring treatment.
* Previously discontinued therapy with deferiprone or deferoxamine because of an adverse drug reaction to either chelator.
* Have received deferiprone in the last five years. However those who have been exposed to deferiprone for ≤ 6 months but not within the last 2 years prior to commencement of this study will be considered eligible to participate.
* Evidence of abnormal liver function (liver enzymes \> 3 times upper limit of normal - entry may be delayed until return to normal).
* Have disorders associated with neutropenia (ANC \< 1.5 x 10\^9/L) or thrombocytopenia (platelet count \<50 x 10\^9/L) in the twelve months prior to start of study medication, except for participants who have been treated with interferon and in whom the ANC has fully recovered. Participants with neutropenia or thrombocytopenia in the last year, which resolved with splenectomy, may be considered for this study.
* Those who refuse to participate in the screening procedures or who are unable to participate in screening procedures or who are unable to comply with requirements of the protocol.
* Receiving other investigational products.
* Those in the opinion of the Investigator, who represent poor medical, psychological or psychiatric risks for whom participation in an investigational trial would be unwise.
* Those who are pregnant, breastfeeding or planning to become pregnant during the study period.
* Metallic objects in his/her body, such as artificial joints, inner ear (cochlear) implants, brain aneurysm clips, pacemakers, and metallic foreign bodies in the eye or other body areas.
* History of malignancy.
* Participants with claustrophobia.
* History of alcohol or drug abuse.
* Participants who are, in the opinion of the Investigator, excessively obese.

Minimum Eligible Age

18 Years

Maximum Eligible Age

36 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No